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Antiretroviral therapy (ART)hasbeen rapidly scaledup inAsiafor
fewyears or almost a decade, dependingon the resource setting in
ndividual country. Since then, the mortality and morbidity of HIV-
nfected patients in the region have signiﬁcantly reduced and the
ualityof lifehasmarkedly improved.Unfortunately, somepatients
xperience treatment failure and HIV drug resistance (HIVDR) is a
ajor reason for this poor outcome. The second chance for success-
ul treatment with the second-line regimens among these patients
elieson the limitedoptionsof antiretroviral agents ineachcountry.
IVDR testing in this setting is beneﬁcial for guiding the appropri-
te second-line regimens. Even if the choices for the second-line
egimens are not really many, the results of HIVDR testing are still
seful for anticipation of the treatment outcomes and preparation
f the ART program. However, the cost of the test and the lim-
ted capability for molecular laboratory are major barriers for the
ccessibility of HIVDR testing in some countries.
After scaling up of ART for years, primary HIVDR has emerged
nd threatens the effectiveness ofARTamongHIV-infectedpatients
ho are initiating ART. The prevalence of primary HIVDR varies
hroughoutAsia. Again, the barriers for HIVDR testing prohibit
he use of this test among antiretroviral-naïve patients who are
lanned to initiate ART. Limited data suggests an increasing trend
f primary HIVDR across the region. Although HIVDR testing prior
o ART initiation is not routinely recommended in most countries
nAsia, identifying the risks of primary HIVDR in each setting and
argeting this test in high-risk groups are important interventions
o minimize the chance of treatment failure in the region. Newer
echnologies and strategies to make HIVDR testing less expen-
ive and more accessible in the country are also very important
o achieve long-term success of national ART program.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.117nfectious Diseases 16S (2012) e2–e157 e47
Type: Oral Presentation
Final Abstract Number: 28.001
Session: New Developments in Viral Diseases
Date: Friday, June 15, 2012
Time: 15:45-17:45
Room: Lotus 11
Viral pathogenicity requires a multipronged strategy to combat
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Background: Viral evasion of the interferon (IFN)-mediated
innate immune response is essential to pathogenic infection, and
depends on the expression of viral IFN-antagonist proteins that
interact with and inhibit host factors of the IFN-response, includ-
ing the transcription factor STAT 1. In vitro studies have suggested
that immune evasion by highly pathogenic viruses such as rabies
(RABV), the causative agent of >55,000 human fatalities/year, and
Nipah virus, involves several IFN-antagonist protein isoforms that
mediate distinct IFN-inhibitory mechanisms in speciﬁc subcellu-
lar compartments. For example, we have shown that the RABV
IFN-antagonist isoforms P1 and P3 inhibit IFN-dependent STAT1
signaling by distinct mechanisms dependent on their differential
localisation in the cytoplasm and nucleus, and at the microtubule
(MT) cytoskeleton. It has thus been hypothesised that the cumula-
tive effect of these mechanisms is required for efﬁcient shut-down
of the IFN response. However, the importance of these in vitro
observations to viral virulence in vivo is unknown.
Methods: To examine the role of different IFN-antagonist iso-
forms in virulence, we used a combined approach to bridge
molecular/cellular approaches with in vivo pathogenicity studies.
Using novel quantitative live-cell imaging approaches/high-end
confocal laser scanning microscopy, IFN-signalling assays and
in vitro protein interaction assays, we characterised the molecular
events underlying the differing functions of P1 and P3, includ-
ing nucleocytoplasmic trafﬁcking, MT-association, and inhibition
of STAT1 signaling, and identiﬁed mutations that can speciﬁ-
cally inhibit these processes. Using reverse genetics, we generated
recombinant RABV defective in these functions, and evaluated
viral infectivity and immune evasion in vitro, and pathogenicity in
infected animals.
Results: The study revealed for the ﬁrst time that mutations
causing defects in speciﬁc properties of the P1 and P3 isoforms,
including nuclear export and MT-association, directly impact their
IFN-antagonistic functions, the sensitivity of infectious virus to IFN,
and virulence in infected animals. Importantly, the data indicate
that the distinct functions of the isoforms make signiﬁcant but par-
tial contributions to viral pathogenicity in vivo, with full virulence
dependent on their combined activity. This data directly support
thehypothesis that viruses have evolvedmulti-pronged, integrated
strategies to mediate an effective counterattack against the host
immune response.
Conclusion: This work contributes signiﬁcantly to our under-
standing of the molecular events at the virus-host interface, and
their importance to viral evasion of innate immunity, and viral
pathogenicity. This is signiﬁcant not only to RABV but also to other
lethal human pathogens, with implications for the development of
new vaccines/antivirals.
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